Upper Tract Urothelial Carcinoma
Conditions
Keywords
HE-stained slides, Tumor microenvironment, Precise subtype, Adjuvant therapy
Brief summary
This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for laUTUC postoperatively.
Interventions
DRUGChemotherapy
Gemicitabin and cisplatin
DRUGImmunotherapy
PD-1/PD-L1
DRUGADC
ADC drug like RC48
Chemotherapy combined with immunotherapy
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Peking University Third Hospital
Fujian Provincial Hospital
Peking University First Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* pathological diagnose of UTUC; * Met more than muscle-invasion stages(pT2+) or lymph nodes metastasis.
Exclusion criteria
* Patients with early-local stages (pTa/T1/Tis) without LNM+ and those with incomplete pathologic and prognostic information were excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DFS | 1 year, 3 years and 5 years | Disease-free survival include death and recurrence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 3 month after the start of treatment until the end of treatment | Response rate |
| OS | 1 year, 3 years and 5 years | Overall survival |
| AE | 1-3 months after starting treatment | adverse effects |
Contacts
Primary ContactChunru Doc. Xu, M.D.
Outcome results
None listed